Skip to main content

Table 3 MRI scorings and findings in corresponding target biopsy by biopsy naivety

From: Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies

  Biopsy naïve (n = 387) Previous benign biopsy (n = 145) p p p
  Total csPCa findings nsPCa findings Total csPCa findings nsPCa findings MRI csPCa nsPCa
PI-RADS score, % (n) % (n) % (n) % (n) & (n) % (n) % (n)    
 ≤ 2 16.8 (65) 26.1 (38) < 0.05
 3 36.2 (140) 16.4 (23) 20.7 (29) 37.9 (55) 12.7 (7) 1.8 (1) 0.7 0.5 < 0.05
 4 23.5 (91) 44.0 (40) 26.3 (24) 20.7 (30) 30.0 (9) 30.0 (9) 0.5 0.2 0.7
 5 23.5 (91) 82.4 (75) 9.9 (9) 15.2 (22) 63.6 (14) 18.2 (4) < 0.05 0.05 0.3
Total 100 (387) 35.7 (138) 16 (62) 100 (145) 20.7 (30) 9.7 (14)    
  1. Clinically significant prostate cancer (csPCa) was defined as ISUP grade group (GG) ≥ 2. Clinically non-significant cancer was defined as GG 1. Comparisons are described using p values from pairwise comparisons of proportions for MRI, csPCa and nsPCa findings between previously biopsied and biopsy-naïve men